Abstract
Around the world, health policy decision makers and payers are compelled to ensure delivery of quality health care under ever-tighter budgetary constraints and increasing demand. This is due to many factors, including ageing populations, expensive health technologies, and financial uncertainty. Yet, despite all the heterogeneity across different drug markets, a constant fact is that costs and cost-effectiveness are crucial determinants of the feasibility and affordability of pharmacotherapy. This chapter will provide an overview of the different approaches to economic evaluation of pharmacotherapies and describe health technology assessment methods used to outline the process in drug reimbursement.
| Original language | English |
|---|---|
| Title of host publication | Encyclopedia of Pharmacy Practice and Clinical Pharmacy |
| Subtitle of host publication | Volumes 1-3 |
| Editors | Zaheer-Ud-Din Babar |
| Place of Publication | Amsterdam The Netherlands |
| Publisher | Elsevier |
| Pages | 420-434 |
| Number of pages | 15 |
| Volume | 1-3 |
| Edition | 1st |
| ISBN (Electronic) | 9780128127360 |
| ISBN (Print) | 9780128127353 |
| DOIs | |
| Publication status | Published - 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cost-benefit
- Cost-effectiveness
- Cost-utility
- Costs
- Economic-evaluations
- Health care
- Health technology assessment
- Incremental cost-effectiveness ratio
- Pharmacotherapy
- Quality of life
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver